Key Points
CEO Paul te Boekhorst files Form 3 for 25,329 non-qualified stock options.
Strike price set at $5.90 per share worth $149,441.
Options vest September 16, 2028 establishing three-year performance timeline.
Initial ownership filing establishes baseline for tracking future insider trading activity.
Insider trading filings reveal what company leaders really think about their stock. When executives file paperwork with the SEC, it signals confidence or caution. ImmuCell Corporation (ICCC) just saw a major filing from its top executive. CEO Paul te Boekhorst disclosed a significant position in non-qualified stock options. This Form 3 filing shows initial ownership details that matter to investors tracking insider activity.
CEO Stock Option Disclosure Details
Paul te Boekhorst, President and CEO of ICCC, filed an initial ownership report on November 7, 2025. The filing covers non-qualified stock options representing the right to purchase 25,329 shares. These options carry a strike price of $5.90 per share, totaling approximately $149,441 in estimated value.
Form 3 filings are required when insiders first acquire reportable securities. This particular filing documents options that vest on September 16, 2028. The three-year timeline suggests a standard executive compensation package aligned with long-term company performance.
What Non-Qualified Stock Options Mean
Non-qualified stock options differ from incentive stock options in tax treatment and flexibility. They give executives the right to buy company shares at a fixed price, regardless of market conditions. With a $5.90 strike price, te Boekhorst benefits if ICCC trades above that level by 2028.
These options represent a significant stake in company success. At current market conditions, the underlying shares could be worth substantially more. The vesting schedule ties executive compensation directly to shareholder value creation over three years.
Insider Filing Signals and Market Implications
Initial ownership filings like this one establish baseline positions for tracking future insider activity. Meyka AI rates ICCC a grade of B, reflecting solid fundamentals and sector positioning. The CEO’s substantial option grant suggests confidence in the company’s growth trajectory through 2028.
Form 3 filings don’t indicate buying or selling activity. Instead, they document what insiders own when they first become subject to SEC reporting requirements. This transparency helps investors understand executive compensation structures and alignment with shareholder interests.
Understanding the SEC Filing Process
The SEC filing shows te Boekhorst’s initial ownership position in ICCC securities. Filing dates and transaction dates can differ significantly, as this November 2025 filing documents September 2028 options. This timing reflects when options were granted versus when they must be reported.
Investors can access complete filing details through the SEC’s EDGAR database. These public records provide crucial transparency into executive compensation and insider positions. Tracking these filings helps identify patterns in insider confidence and company strategy.
Final Thoughts
Paul te Boekhorst’s Form 3 filing reveals a substantial non-qualified stock option position in ImmuCell Corporation. The 25,329 shares at $5.90 strike price demonstrate executive alignment with long-term shareholder value. This initial ownership disclosure establishes a baseline for monitoring future insider trading activity at ICCC through 2028 and beyond.
FAQs
Form 3 is an initial SEC report filed when insiders become subject to reporting requirements. It documents all reportable securities owned at that time, establishing a baseline for future insider trading disclosures.
Non-qualified stock options grant executives the right to purchase company shares at a fixed strike price with flexible exercise terms and distinct tax treatment compared to incentive stock options.
The transaction date indicates when options vest and become exercisable, while the filing date reflects when the SEC report was submitted—typically months after the original grant date.
Disclaimer:
The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Insider trading data is sourced from public SEC filings. This is not financial advice. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)